Skip to main content

Table 1 Clinical features of the study population (n = 108)

From: The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma

Age at diagnosis 52 (26–79)
Personal history of cancer 8.3% (9/108)
Family history of cancer 21.3% (23/108)
FIGO Stage
 FIGO stage I 45.3% (48/106)
 FIGO stage II 17.0% (18/106)
 FIGO stage III 29.2% (31/106)
 FIGO stage IV 8.5% (9/106)
Extent of debulking
 Residual disease = 0 cm (%) 79.4% (81/102)
 Residual disease ≤1 cm (%) 88.2% (90/102)
Platinum response
 Platinum-sensitive 69.6% (71/102)
 Platinum-resistant 30.4% (31/102)
Follow-up time (mean, range) 46 (1–178)
Disease status at last follow up
 Dead (%) 46.1% (48/104)
 Alive with disease (%) 20.2% (21/104)
 No evidence of disease 33.7% (35/104)
  1. Abbreviations: FIGO The International Federation of Gynecology and Obstetrics